CRC-403: A phase 1/2 study of bbT369, a dual targeting CAR T-cell drug product with a gene edit, in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL). A first-in-human phase 1 study of oral ...
Persist NetworkX Graphs to ArangoDB. Reload NetworkX Graphs from ArangoDB. Perform CRUD on ArangoDB Graphs via NetworkX. Run algorithms (CPU & GPU) on ArangoDB Graphs via NetworkX. Not really. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results